Analyst consensus rating
Apogee Therapeutics Analyst Rating: Hold
Direct answer
Apogee Therapeutics's consensus rating is Hold.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $134.62.
Forecast evidence checked November 3, 2026.
Get free Apogee Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $135.07
- Average price target
- $134.62
- High price target
- $135.11
- Low price target
- $133.00
- Low target gap
- -1.5%
- Target upside
- -0.3%
- High target gap
- +0%
- Target range width
- 1.6%
- Consensus rating
- Hold
- Analysts
- 5
- Evidence date
- November 3, 2026
- Valid through
- November 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Apogee Therapeutics?
Apogee Therapeutics has a verified Hold consensus. The same dataset has an average price target of $134.62.
How far are Apogee Therapeutics's low and high targets from the recorded price?
The low target implies -1.5%, while the high target implies +0%.
How many analysts are included in Apogee Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Apogee Therapeutics's target upside or downside calculated?
The average target of $134.62 is divided by the recorded price of $135.07, then one is subtracted to produce -0.3%. This does not guarantee a future return.
When was Apogee Therapeutics's analyst forecast verified?
The data was verified on 2026-11-03. The dataset is valid through 2026-11-10.